J. Goldman & Co LP increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 639.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,683 shares of the company's stock after purchasing an additional 97,446 shares during the period. J. Goldman & Co LP owned 0.16% of Replimune Group worth $1,365,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC boosted its stake in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after acquiring an additional 5,922 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its stake in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after acquiring an additional 8,183 shares in the last quarter. XTX Topco Ltd acquired a new position in Replimune Group in the fourth quarter valued at $137,000. Finally, Freestone Grove Partners LP acquired a new position in Replimune Group in the fourth quarter valued at $140,000. Institutional investors and hedge funds own 92.53% of the company's stock.
Analyst Ratings Changes
Several equities analysts have issued reports on the stock. BMO Capital Markets upped their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Finally, HC Wainwright upped their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $19.43.
View Our Latest Report on REPL
Replimune Group Stock Performance
Shares of NASDAQ:REPL traded up $0.62 on Friday, reaching $7.85. The company's stock had a trading volume of 1,666,221 shares, compared to its average volume of 904,125. The stock's 50-day moving average is $8.95 and its two-hundred day moving average is $11.32. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The stock has a market capitalization of $604.57 million, a P/E ratio of -2.56 and a beta of 0.68.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.
Replimune Group Profile
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
See Also
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
